Evolent Health, Inc. (NYSE:EVH) Director Buys $25,517.55 in Stock

Evolent Health, Inc. (NYSE:EVH) Director Diane Holder purchased 2,735 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were purchased at an average cost of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the purchase, the director now directly owns 70,584 shares in the company, valued at $658,548.72. The trade was a 4.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Evolent Health Trading Up 1.0 %

NYSE EVH opened at $9.49 on Thursday. Evolent Health, Inc. has a one year low of $8.35 and a one year high of $34.07. The company’s 50 day moving average price is $10.26 and its 200 day moving average price is $17.23. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -11.57 and a beta of 1.49.

Evolent Health (NYSE:EVH) last posted its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The business had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. On average, sell-side analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current year.

Institutional Trading of Evolent Health

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in Evolent Health by 12.8% in the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after acquiring an additional 1,426,747 shares in the last quarter. Vanguard Group Inc. grew its position in Evolent Health by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 11,171,199 shares of the technology company’s stock valued at $125,676,000 after acquiring an additional 259,781 shares in the last quarter. Engaged Capital LLC grew its position in Evolent Health by 35.5% in the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company’s stock valued at $60,804,000 after acquiring an additional 1,415,300 shares in the last quarter. Cadian Capital Management LP acquired a new stake in Evolent Health in the fourth quarter valued at approximately $58,781,000. Finally, Eventide Asset Management LLC grew its position in Evolent Health by 1.7% in the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock valued at $107,580,000 after acquiring an additional 64,985 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EVH. Oppenheimer decreased their price target on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. JPMorgan Chase & Co. cut their price objective on shares of Evolent Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Monday. Citigroup cut their price objective on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Evolent Health in a report on Friday, February 21st. Finally, Piper Sandler reiterated an “overweight” rating and set a $16.00 price objective (down from $17.00) on shares of Evolent Health in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.